{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:22:36Z","timestamp":1761740556110},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Development of portosystemic collateral vessels and gastroesophageal varices is responsible for the most serious clinical consequences of portal hypertension, but effective clinical therapies are limited. Here we developed and investigated the therapeutic potential of an innovative liposomally-formulated short-interfering RNA (siRNA) technology based on clinical stage components, capable to attenuate production of the endothelial kinase insert domain receptor (KDR), which controls portosystemic collateralization and contributes to disease progression and aggravation. These siRNAs were first validated <jats:italic>in vitro<\/jats:italic>, and then, their therapeutic potential on portosystemic collateralization and pathological angiogenesis was tested <jats:italic>in vivo<\/jats:italic> in mouse models of portal hypertension (portal vein-ligation). siRNA<jats:sup>KDR<\/jats:sup>-lipoplexes efficiently transported siRNA<jats:sup>KDR<\/jats:sup> to vascular endothelial cells in mesenteric microvenules and portal vein of portal hypertensive mice, where collaterogenesis and angiogenesis take place. This systemic treatment significantly downregulated pathological KDR overexpression, without causing complete KDR knockout, preserving homeostatic baseline KDR levels and thus limiting adverse effects. siRNA<jats:sup>KDR<\/jats:sup>-lipoplex-induced endothelial-specific KDR knockdown drastically reduced by 73% the portosystemic collateralization, and impaired the pathologic angiogenic potential of vascular endothelial cells at different levels (cell proliferation, sprouting and remodeling). Targeting endothelial KDR with therapeutic siRNA<jats:sup>KDR<\/jats:sup>-lipoplexes could be a promising and plausible treatment modality for attenuating the formation of portosystemic collaterals in a clinical setting.<\/jats:p>","DOI":"10.1038\/s41598-017-14818-7","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T09:13:39Z","timestamp":1509009219000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension"],"prefix":"10.1038","volume":"7","author":[{"given":"Javier","family":"Gallego","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Garcia-Pras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Mejias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Pell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Schaeper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"14818_CR1","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1053\/j.gastro.2008.03.007","volume":"134","author":"AJ Sanyal","year":"2008","unstructured":"Sanyal, A. J., Bosch, J., Blei, A. & Arroyo, V. Portal hypertension and its complications. Gastroenterology. \n                           134, 1715\u20131728 (2008).","journal-title":"Gastroenterology."},{"key":"14818_CR2","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/S0140-6736(08)60383-9","volume":"371","author":"D Schuppan","year":"2008","unstructured":"Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet. \n                           371, 838\u2013851 (2008).","journal-title":"Lancet."},{"key":"14818_CR3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMra0901512","volume":"362","author":"G Garcia-Tsao","year":"2010","unstructured":"Garcia-Tsao, G. & Bosch, J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. \n                           362, 823\u2013832 (2010).","journal-title":"N Engl J Med."},{"key":"14818_CR4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJMra003007","volume":"345","author":"AI Sharara","year":"2001","unstructured":"Sharara, A. I. & Rockey, D. C. Gastroesophageal variceal hemorrhage. N Engl J Med. \n                           345, 669\u2013681 (2001).","journal-title":"N Engl J Med."},{"key":"14818_CR5","doi-asserted-by":"crossref","unstructured":"Fernandez, M. & Abraldes, J.G. Gastroesophageal varices. In: Liver Pathophysiology: Therapies and Antioxidants (ed. Muriel, P.) 451\u2013473 (Academic Press, Elsevier, 2017).","DOI":"10.1016\/B978-0-12-804274-8.00035-7"},{"key":"14818_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jhep.2005.04.002","volume":"43","author":"R Moreau","year":"2005","unstructured":"Moreau, R. VEGF induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol. \n                           43, 6\u20138 (2005).","journal-title":"J Hepatol."},{"key":"14818_CR7","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","volume":"126","author":"M Fernandez","year":"2004","unstructured":"Fernandez, M., Vizzutti, F., Garcia-Pagan, J. C., Rodes, J. & Bosch, J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology. \n                           126, 886\u2013894 (2004).","journal-title":"Gastroenterology."},{"key":"14818_CR8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jhep.2005.02.022","volume":"43","author":"M Fernandez","year":"2005","unstructured":"Fernandez, M. et al. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. \n                           43, 98\u2013103 (2005).","journal-title":"J Hepatol."},{"key":"14818_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.21785","volume":"46","author":"M Fernandez","year":"2007","unstructured":"Fernandez, M. et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. \n                           46, 1208\u20131217 (2007).","journal-title":"Hepatology."},{"key":"14818_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/hep.22758","volume":"49","author":"M Mejias","year":"2009","unstructured":"Mejias, M. et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology. \n                           49, 1245\u20131256 (2009).","journal-title":"Hepatology."},{"key":"14818_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.1478-3231.2006.01308.x","volume":"26","author":"AM Geerts","year":"2006","unstructured":"Geerts, A. M. et al. Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study. Liver Int. \n                           26, 889\u2013898 (2006).","journal-title":"Liver Int."},{"key":"14818_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2009.06.024","volume":"51","author":"T Reiberger","year":"2009","unstructured":"Reiberger, T. et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. \n                           51, 865\u2013873 (2009).","journal-title":"J Hepatol."},{"key":"14818_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jhep.2014.01.025","volume":"60","author":"P Schwabl","year":"2014","unstructured":"Schwabl, P. et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. J Hepatol. \n                           60, 1135\u20131142 (2014).","journal-title":"J Hepatol."},{"key":"14818_CR14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/hep.25625","volume":"56","author":"HC Huang","year":"2012","unstructured":"Huang, H. C. et al. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology. \n                           56, 248\u2013258 (2012).","journal-title":"Hepatology."},{"key":"14818_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/eci.12636","volume":"46","author":"SJ Hsu","year":"2016","unstructured":"Hsu, S. J. et al. Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats. Eur J Clin Invest. \n                           46, 572\u2013580 (2016).","journal-title":"Eur J Clin Invest."},{"key":"14818_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/nm0603-653","volume":"9","author":"P Carmeliet","year":"2003","unstructured":"Carmeliet, P. Angiogenesis in health and disease. Nat Med. \n                           9, 653\u2013660 (2003).","journal-title":"Nat Med."},{"key":"14818_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente, M., Gerhardt, H. & Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell. \n                           146, 873\u2013887 (2011).","journal-title":"Cell."},{"key":"14818_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nat Med. \n                           9, 669\u2013676 (2003).","journal-title":"Nat Med."},{"key":"14818_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","volume":"7","author":"AK Olsson","year":"2006","unstructured":"Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signaling. In control of vascular function. Nat Rev Mol Cell Biol. \n                           7, 359\u2013371 (2006).","journal-title":"Nat Rev Mol Cell Biol."},{"key":"14818_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons, M., Gordon, E. & Claesson-Welsh, L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. \n                           17, 611\u2013625 (2016).","journal-title":"Nat Rev Mol Cell Biol."},{"key":"14818_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.22872","volume":"49","author":"VH Shah","year":"2009","unstructured":"Shah, V. H. & Bruix, J. Antiangiogenic therapy: not just for cancer anymore? Hepatology. \n                           49, 1066\u20131068 (2009).","journal-title":"Hepatology."},{"key":"14818_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","volume":"50","author":"M Fernandez","year":"2009","unstructured":"Fernandez, M. et al. Angiogenesis in liver disease. J Hepatol. \n                           50, 604\u2013620 (2009).","journal-title":"J Hepatol."},{"key":"14818_CR23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/hep.27343","volume":"61","author":"M Fernandez","year":"2015","unstructured":"Fernandez, M. Molecular pathophysiology of portal hypertension. Hepatology. \n                           61, 1406\u20131415 (2015).","journal-title":"Hepatology."},{"key":"14818_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. \n                           391, 806\u2013811 (1998).","journal-title":"Nature."},{"key":"14818_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/35078107","volume":"411","author":"SM Elbashir","year":"2001","unstructured":"Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. \n                           411, 494\u2013498 (2001).","journal-title":"Nature."},{"key":"14818_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature08956","volume":"464","author":"ME Davis","year":"2010","unstructured":"Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. \n                           464, 1067\u20131070 (2010).","journal-title":"Nature."},{"key":"14818_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/sj.gt.3302777","volume":"13","author":"A Santel","year":"2006","unstructured":"Santel, A. et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. \n                           13, 1222\u20131234 (2006).","journal-title":"Gene Ther."},{"key":"14818_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mvr.2008.02.004","volume":"76","author":"M Aleku","year":"2008","unstructured":"Aleku, M. et al. Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res. \n                           76, 31\u201341 (2008).","journal-title":"Microvasc Res."},{"key":"14818_CR29","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/sj.gt.3302778","volume":"13","author":"A Santel","year":"2006","unstructured":"Santel, A. et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. \n                           13, 1360\u20131370 (2006).","journal-title":"Gene Ther."},{"key":"14818_CR30","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-10-1994","volume":"16","author":"A Santel","year":"2010","unstructured":"Santel, A. et al. Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res. \n                           16, 5469\u20135480 (2010).","journal-title":"Clin Cancer Res."},{"key":"14818_CR31","doi-asserted-by":"publisher","first-page":"9788","DOI":"10.1158\/0008-5472.CAN-08-2428","volume":"68","author":"M Aleku","year":"2008","unstructured":"Aleku, M. et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. \n                           68, 9788\u20139798 (2008).","journal-title":"Cancer Res."},{"key":"14818_CR32","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4161\/cbt.5.12.3468","volume":"5","author":"C Landen","year":"2006","unstructured":"Landen, C. et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther. \n                           5, 1708\u20131713 (2006).","journal-title":"Cancer Biol Ther."},{"key":"14818_CR33","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/0092-8674(89)90343-7","volume":"57","author":"RL Williams","year":"1989","unstructured":"Williams, R. L. et al. Endothelioma cells expressing the polyoma middle T oncogene induce hemangiomas by host cell recruitment. Cell. \n                           57, 1053\u20131063 (1989).","journal-title":"Cell."},{"key":"14818_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.gastro.2015.11.038","volume":"150","author":"V Calderone","year":"2016","unstructured":"Calderone, V. et al. Sequential functions of CPEB1 and CPEB4 regulate pathologic expression of VEGF and angiogenesis in chronic liver disease. Gastroenterology. \n                           150, 982\u2013997 (2016).","journal-title":"Gastroenterology."},{"key":"14818_CR35","first-page":"3403","volume":"63","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. \n                           63, 3403\u20133412 (2003).","journal-title":"Cancer Res."},{"key":"14818_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/mt.2013.291","volume":"22","author":"V Fehring","year":"2014","unstructured":"Fehring, V. et al. Delivery of therapeutic siRNA to the lung endothelium via novel lipoplex formulation DACC. Mol Ther. \n                           22, 811\u2013820 (2014).","journal-title":"Mol Ther."},{"key":"14818_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.1840180224","volume":"18","author":"M Fernandez","year":"1993","unstructured":"Fernandez, M. et al. Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology. \n                           18, 389\u2013393 (1993).","journal-title":"Hepatology."},{"key":"14818_CR38","doi-asserted-by":"publisher","first-page":"e13876","DOI":"10.7554\/eLife.13876","volume":"5","author":"S Sarabipour","year":"2016","unstructured":"Sarabipour, S., Ballmer-Hofer, K. & Hristova, K. VEGFR-2 conformational switch in response to ligand binding. Elife. \n                           5, e13876, https:\/\/doi.org\/10.7554\/eLife.13876 (2016).","journal-title":"Elife."},{"key":"14818_CR39","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1126\/science.1690453","volume":"247","author":"PJ Newman","year":"1990","unstructured":"Newman, P. J. et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science. \n                           247, 1219\u20131222 (1990).","journal-title":"Science."},{"key":"14818_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2010.01.004","volume":"52","author":"M Mejias","year":"2010","unstructured":"Mejias, M. et al. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol. \n                           52, 529\u2013539 (2010).","journal-title":"J Hepatol."},{"key":"14818_CR41","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov, Y. et al. Off-target effects by siRNA can induce toxic phenotype. RNA. \n                           12, 1188\u20131196 (2006).","journal-title":"RNA."},{"key":"14818_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1126\/science.3941904","volume":"231","author":"BL Langille","year":"1986","unstructured":"Langille, B. L. & O\u2019Donnell, F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science. \n                           231, 405\u2013407 (1986).","journal-title":"Science."},{"key":"14818_CR43","doi-asserted-by":"publisher","first-page":"18393","DOI":"10.1074\/jbc.274.26.18393","volume":"274","author":"KD Chen","year":"1999","unstructured":"Chen, K. D. et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem. \n                           274, 18393\u201318400 (1999).","journal-title":"J Biol Chem."},{"key":"14818_CR44","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/01.RES.0000089257.94002.96","volume":"93","author":"ZG Jin","year":"2003","unstructured":"Jin, Z. G. et al. Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res. \n                           93, 354\u2013363 (2003).","journal-title":"Circ Res."},{"key":"14818_CR45","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature03952","volume":"437","author":"E Tzima","year":"2005","unstructured":"Tzima, E. et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature. \n                           437, 426\u2013431 (2005).","journal-title":"Nature."},{"key":"14818_CR46","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM198806093182303","volume":"318","author":"P Libby","year":"1988","unstructured":"Libby, P., Warner, S. J., Salomon, R. N. & Birinyi, L. K. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. \n                           318, 1493\u20131498 (1988).","journal-title":"N Engl J Med."},{"key":"14818_CR47","first-page":"286","volume":"144","author":"MD Botney","year":"1994","unstructured":"Botney, M. D., Bahadori, L. & Gold, L. I. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol. \n                           144, 286\u2013295 (1994).","journal-title":"Am J Pathol."},{"key":"14818_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1074\/jbc.M112.417451","volume":"288","author":"R Mazor","year":"2013","unstructured":"Mazor, R. et al. Matrix metalloproteinase-1-mediated up-regulation of vascular endothelial growth factor-2 in endothelial cells. J Biol Chem. \n                           288, 598\u2013607 (2013).","journal-title":"J Biol Chem."},{"key":"14818_CR49","first-page":"697","volume":"77","author":"C Gerlach","year":"1997","unstructured":"Gerlach, C., Golding, M., Larue, L., Alison, M. R. & Gerdes, J. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest. \n                           77, 697\u2013698 (1997).","journal-title":"Lab Invest."},{"key":"14818_CR50","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/gutjnl-2015-311157","volume":"66","author":"E Garcia-Pras","year":"2017","unstructured":"Garcia-Pras, E. et al. Role and therapeutic potential of vascular stem\/progenitor cells in pathological neovascularisation during chronic portal hypertension. Gut. \n                           66, 1306\u20131320 (2017).","journal-title":"Gut."},{"key":"14818_CR51","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1161\/01.RES.0000255691.76142.4a","volume":"100","author":"WC Aird","year":"2007","unstructured":"Aird, W. C. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res. \n                           100, 158\u2013173 (2007).","journal-title":"Circ Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14818-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14818-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T12:51:39Z","timestamp":1671799899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-14818-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["14818"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-14818-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]},"assertion":[{"value":"26 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14791"}}